

**Menopause: diagnosis and management (update) Guideline Committee Meeting 11**

**Date:** Monday 22 May 2023  
**Location** Virtual meeting via Zoom  
**Minutes:** **Final**

<b>Committee members present:</b>	
Gillian Baird	Present for notes 1-10
Martha Hickey	Present for notes 1-10
Haitham Hamoda	Present for notes 1-10
Gillian Reeves	Present for notes 1-10
Hayley Berry	Present for notes 1-10
Sarah Hillman	Present for notes 1-9
Roopen Arya items	Present for notes 1-4
Nina Kuypers	Present for notes 1-10
Eef Hogervorst	Present for notes 1-10
Lorraine Griffiths	Present for notes 1-10
Karina Bowkett	Present for notes 6 -10
Louise Massey	Present for notes 6 -10
Anita Sharma	Present for notes 1-8
Anne Armstrong	Present for notes 5-8
John Stevenson	Present for notes 1-4
Jenny Van Heerden	Present for notes 1-8

<b>In attendance:</b>		
Katharina Dworzynski	Guideline Lead	Present for notes 1-10
Melissa Bolessa	Project Manager	Present for notes 1-10
Nathan Bromham	Senior Systematic Reviewer	Present for notes 1-10
Agnesa Mehmeti	Systematic Reviewer	Present for notes 1-10
Nick O'Callaghan-Staples	Guideline Commissioning Manager	Present for notes 2-10
Anja Fricke	Systematic Reviewer	Present for notes 1-10
Katriona O'Donoghue	Systematic Reviewer	Present for notes 1-2 & 4-10
Stephen Murphy	Clinical Advisor	Present for notes 3-10
Shalmali Deshpande	Systematic Reviewer	Present for notes 1-10
James Hawkins	Senior Economist	Present for notes 9 -10
Edgar Masanga	Associate Assessment Lead	Present for notes 1-10
Astrid Aregui	Senior Medical Editor	Present for notes 3-10

Georgina Fletcher	Media relations executive – Media Relations	Present for notes 1-10
-------------------	---	------------------------

**APOLOGIES:**

David Armstrong	Co-opted GC member
-----------------	--------------------

**1. Welcome, housekeeping, aims of the day and apologies**

The Chair welcomed the Committee members and attendees to the 11<sup>th</sup> guideline committee meeting on Menopause: diagnosis and management (update).

The Chair asked the committee to review the minutes and the minutes were confirmed as accurate.

The Chair requested for any new declarations of interest to be shared with the group.

Name	Role	Description of interest	Type of interest	Decision taken
Professor Martha Hickey	Topic advisor	Radio Interview on the ABC Health Report with Radio National. Topic was menopause (May 2023). Declared 10.05.2023	Direct – non-financial professional and personal interests	Declare and participate. Agreed by developer Guideline Lead and Committee Chair  Rationale: This was related generally to the topic of the guideline but did not go into the details of the topics covered in the scope.
Professor Martha Hickey	Topic advisor	Publication – International guidelines in care after risk-reducing salpingo-oophorectomy in BRCA1/2 <a href="https://pubmed.ncbi.nlm.nih.gov/37132126/">https://pubmed.ncbi.nlm.nih.gov/37132126/</a> May 2023 published in British J Obstetrics and Gynaecology. Declared 10.05.2023	Direct – non-financial professional and personal interests	Declare and participate. Agreed by developer Guideline Lead and Committee Chair  Rationale: This is outside the scope of the guideline.
Mr Haitham Hamoda	Topic advisor	Published article: An evaluation of menopause service delivery during the COVID-19 pandemic. Post Reprod Health. 2023 May 8:20533691231174379. doi: 10.1177/20533691231174379. Declared:20.05.2023	Direct – non-financial professional and personal interests	Declare and participate. Agreed by developer Guideline Lead and Committee Chair  Rationale: This activity is non-specific to the scope of the guideline.
Mr Haitham Hamoda	Topic advisor	Quote to Daily Mail on effects of Mirena within HRT compared to other progestogen (May 2023) Declared: 20.05.2023	Direct – non-financial professional and personal interests	Declare and participate. Agreed by developer Guideline Lead and Committee Chair  Rationale: This activity is non-specific to the scope of the guideline.

John Stevenson	Co-opted member	International Menopause Society Webinar: Menopause in Obese Patients and Cardiovascular Risk. Declared 17.05.2023	Indirect interest	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair</p> <p>Rationale: This is related to the cardiovascular review but not specifically restricted to HRT it is therefore non-specific.</p>
Sarah Hillman	Committee member - GP	Took part in a focus group about access to menopause care led by wellbeing of women and Holland and Barrett. Declared: 17.05.2023	Direct – non-financial professional and personal interests	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair</p> <p>Rationale: Service organisation including how to access care is outside the scope of the guideline.</p>
Eef Hogervorst	Committee member	Gave an invited keynote for CRN East Midlands Dementia workshop on menopause and dementia risk but this did not include any data from NICE reviews but the independent reviews I wrote on this topic in 2021 (see earlier declaration).	Direct – non-financial professional and personal interests	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair</p> <p>Rationale: Whilst this is relevant to the scope of the guideline, the review this was based on was not included in the evidence review and therefore the talk was not specific to the topic under discussion.</p>
Eef Hogervorst	Committee member	Developing a survey for HR management of menopausal symptoms for women and managers at Loughborough University.	Direct – non-financial professional and personal interests	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair</p> <p>Rationale: This activity is non-specific to the scope of the guideline.</p>

They newly declared interests did not impact on the participation of committee members on matters under discussion for this meeting. A previously declared interest by John Stephenson did impact on participation. This was a partial exclusion from the cardiovascular topic meaning that the committee member was participating in the discussion and provided expertise to the committee but was not involved in the wording of the recommendation.

## 2. Revisiting early menopause recommendations

Katharina Dworzynski, Guideline Lead and Gillian Baird, Committee Chair, led on revisiting early menopause recommendations.

The committee discussed editorial comments from Document 4 and considered absolute numbers from Document 5

## 3. Revisiting cardiovascular recommendations.

<p>Katharina Dworzynski, Guideline Lead and Gillian Baird, Committee Chair, led on revisiting cardiovascular recommendations.</p> <p>The committee discussed Clinical evidence from Document 6 as well as considered editorial comments from Document 4 and absolute numbers from Document 5. The committee further discussed the comparison between new recommendations to NG23 and summarised reasons for potential changes.</p>
<p><b>4. Revisiting stroke recommendations</b></p>
<p>Katharina Dworzynski, Guideline Lead and Gillian Baird, Committee Chair, led on revisiting stroke recommendations, including integration of RCT and observational evidence.</p> <p>The committee discussed Clinical evidence from Document 6 as well as considered editorial comments from Document 4 and absolute numbers from Document 5. The committee further discussed the comparison between new recommendations to NG23 and summarised reasons for potential changes.</p>
<p><b>5. Revisiting ovarian cancer recommendations</b></p>
<p>Katharina Dworzynski, Guideline Lead and Gillian Baird, Committee Chair, led on revisiting ovarian cancer recommendations.</p> <p>The committee looked at the absolute number table from Document 5 and went over editorial comments from Document 4.</p>
<p><b>6. Lay member forum</b></p>
<p>The committee members held a forum where discussions were made on key points from the revisited recommendations.</p>
<p><b>7. Revisiting breast cancer recommendations.</b></p>
<p>Katharina Dworzynski, Guideline Lead and Gillian Baird, Committee Chair, led on revisiting breast cancer recommendations.</p> <p>The committee discussed editorial comments from Document 4 and absolute numbers from Document 5. The committee further discussed the comparison between new recommendations to NG23 and summarised reasons for potential changes.</p>
<p><b>8. Revisiting endometrial cancer recommendations</b></p>
<p>Katharina Dworzynski, Guideline Lead and Gillian Baird, Committee Chair, led on revisiting endometrial cancer recommendations.</p> <p>The committee discussed editorial comments from Document 4 and absolute numbers from Document 5. The committee further discussed the comparison between new recommendations to NG23 and summarised reasons for potential changes.</p>
<p><b>9. Revisiting genitourinary symptom management recommendations</b></p>

Katharina Dworzynski, Guideline Lead and Gillian Baird, Committee Chair and James Hall, Senior Economist led on revisiting genitourinary recommendations.

The committee discussed editorial comments from Document 4 and edited draft recommendations continuing from the last meeting, they also considered ospemifene as part of their discussions.

**10. Summary of actions & any other business**

Gillian Baird, Committee Chair summarised the actions and next steps. The next meeting will be on Tuesday 27 June 2023.

**Location of next meeting:** Tuesday 27 June 2023, virtually via Zoom.